Spirobicyclic analogues

Patent metadata

Field	Value
Publication number	US-11059850-B2
Application number	US-201816769793-A
Country	US
Kind code	B2
Filing date	Dec 6, 2018
Priority date	Dec 8, 2017
Publication date	Jul 13, 2021
Grant date	Jul 13, 2021

Abstract

The present invention relates to novel spirobicyclic analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

First claim

The invention claimed is:

1. A compound of Formula (I)

wherein
R 1 represents hydrogen or —C(═O)—C 1-4 alkyl;
R 2 represents hydrogen or —C(═O)—C 1-4 alkyl;
X represents hydrogen;
Y represents —O—, —CH 2 —or —CF 2 —;
Q 1 represents CR 6a ;
Q 2 represents N or CR 6b ;
R 6a and R 6b each independently represent hydrogen, halogen, C 1-4 alkyl, —NR 9a R 9b , or C 1-4 alkyl substituted with one, two or three halo atoms;
R 9a and R 9b each independently represent hydrogen or C 1-4 alkyl;
R 3a represents hydrogen, halo, —NR 7a R 7b , C 1-4 alkyl, C 2-4 alkenyl, C 3-6 cycloalkyl, —OH, or —O—C 1-4 alkyl;
R 7a represents hydrogen;
R 7b represents hydrogen, C 3-6 cycloalkyl, or C 1-4 alkyl;
R 4a represents hydrogen, halo, —NR 8a R 8b , or C 1-4 alkyl;
L represents —CH 2 —, —O—CH 2 —, —CH 2 —O—, or —O—;
R 5 represents Ar or Het; and in case L represents —O— or —O—CH 2 —, R 5 can also represent hydrogen;
Ar represents phenyl optionally substituted with one or more halo substituents; and
Het represents a monocyclic or bicyclic ring system selected from the group consisting of (a-1), (a-2), (a-3), (a-4), (a-5), (a-6) and (a-7):

wherein said monocyclic or bicyclic aromatic ring system is optionally substituted with one or more substituents each independently selected from the group consisting of halo and —NH 2;
or a pharmaceutically acceptable addition salt or a solvate thereof.

2. The compound according to claim 1 , wherein
Y represents —O— or —CH 2 —;
R 6a and R 6b represent hydrogen;
R 3a represents halo or —NR 7a R 7b ;
R 7b represents hydrogen;
R 4a represents hydrogen;
R 5 represents Ar or Het; and in case L represents —O— or —O—CH 2 —, R 5 can also represent hydrogen; and
Ar represents phenyl.

3. The compound according to claim 1 , wherein
R 1 represents hydrogen;
R 2 represents hydrogen;
Y represents —O—;
Q 2 represents N;
R 6a represents hydrogen;
R 3a represents —NR 7a R 7b ;
R 7b represents hydrogen;
R 4a represents hydrogen;
L represents —O—;
R 5 represents Het; and
Het represents (a-1), optionally substituted with one or more substituents each independently selected from the group consisting of halo and —NH 2.

4. The compound according to claim 1 , wherein R 1 and R 2 represent hydrogen.

5. The compound according to claim 1 , wherein R 1 represents —C(═O)—C 1-4 alkyl; and R 2 represents —C(═O)—C 1-4 alkyl.

6. The compound according to claim 1 , wherein Y represents —O—.

7. The compound according to claim 1 , wherein Y represents —CH 2 —or —CF 2 —.

8. The compound according to claim 1 , wherein R 5 represents Het.

9. The compound according to claim 1 , wherein R 3a represents halo or —NR 7a R 7b .

10. The compound according to claim 1 , wherein R 3a represents —NR 7a R 7b ; and R 7a and R 7b represent hydrogen.

11. The compound according to claim 1 , wherein Q 2 represents N.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to claim 1 .

13. A method of treating a disease or condition selected from a blood disorder, metabolic disorders, autoimmune disorders, cancer, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, sperm motility, transplantation rejection, graft rejection, and lung injuries: comprising administering to a subject a compound of claim 1 or a pharmaceutically acceptable salt thereof.

14. The method according to claim 13 wherein the disease or condition is cancer.

15. A compound of Formula (XXX)

wherein
Y represents —O—, —CH 2 —or —CF 2 —;
R a represents hydrogen or a hydroxyl protecting group;
R b represents —OH, ═O, —CH 2 —OH, or ═CH 2 ;
wherein the bond towards R b represents a single bond in case R b represents —OH or —CH 2 —OH, or a double bond in case R b represents ═O or ═CH 2 ;
R cl and R c2 represent —C(═O)—C 1-4 alkyl, benzoyl optionally substituted with one or two substituents each independently selected from —CH 3 and —OCH 3 , benzyl optionally substituted with one or two substituents each independently selected from —CH 3 and —OCH 3 , or —CH 2 —napthyl optionally substituted with one or two substituents each independently selected from —CH 3 and —OCH 3 ;
or R c1 and R c2 taken together represent —C(C 1-4 alkyl) 2 -;
or a pharmaceutically acceptable addition salt or a solvate thereof.

16. The compound of claim 15 , wherein the hydroxyl protecting group is C 1-4 alkyl, t-butyldimethylsilyl, C 1-4 alkyl—O—C 1-4 alkyl, tetrahydropyranyl, allyl, t-butyldiphenylsilyl, benzyl, —C(═O)—C 1-4 alkyl, or —C(═O)—phenyl.

17. A method of making a compound of Formula I of claim 1 , comprising contacting a compound of Formula XXX with a suitable acid;
wherein the compound of Formula XXX has the structure

wherein
Y represents —O—, —CH 2 —or —CF 2 —;
R a represents hydrogen or a hydroxyl protecting group;
R b represents —OH, ═O, —CH 2 —OH, or ═CH 2 ;
wherein the bond towards R b represents a single bond in case R b represents —OH or —CH 2 —OH, or a double bond in case R b represents ═O or ═CH 2 ;
R c1 and R c2 represent —C(═O)—C 1-4 alkyl, benzoyl optionally substituted with one or two substituents each independently selected from —CH 3 and —OCH 3 , benzyl optionally substituted with one or two substituents each independently selected from —CH 3 and —OCH 3 , or —CH 2 —napthyl optionally substituted with one or two substituents each independently selected from —CH 3 and —OCH 3 ;
or R c1 and R c2 taken together represent —C(C 1-4 alkyl) 2 -;
or a pharmaceutically acceptable addition salt or a solvate thereof.

18. The method of claim 17 , comprising contacting the compound of Formula XXX with an acid anhydride after contacting with the suitable acid.

19. The method of claim 18 , wherein the acid anhydride has the formula (C 1-4 alkylC═O) 2 O.

20. The method of claim 17 , wherein the suitable acid is HCl.

21. The method of claim 17 , wherein the hydroxyl protecting group is C 1-4 alkyl, t-butyldimethylsilyl, C 1-4 alkyl—O—C 1-4 alkyl, tetrahydropyranyl, allyl, t-butyldiphenylsilyl, benzyl, —C(═O)—C 1-4 alkyl, or —C(═O)—phenyl.

Assignees

• Janssen Pharmaceutica Nv

Inventors

• Verhoeven Jonas
• Verniest Guido Alfons F
• Thuring Johannes Wilhelmus John F
• Wu Tongfei
• Pande Vineet
• Meerpoel Lieven
• Brehmer Dirk
• Sun Weimei
• Denmark Scott E

Classifications

• C07D317/44

  ortho- or peri-condensed with carbocyclic rings or ring systems · CPC title

• C07H19/167 Primary

  with ribosyl as the saccharide radical · CPC title

• C07H19/14

  Pyrrolo-pyrimidine radicals · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D307/94

  spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins · CPC title